Findings of Research Misconduct, 33137 [2017-15159]
Download as PDF
<![CDATA[
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Federal Register / Vol. 82, No. 137 / Wednesday, July 19, 2017 / Notices
The meeting agenda will include: (1)
Presentations and discussion on the
processes states use to identify and
follow up on out of range newborn
screening results; (2) a presentation on
phase one of the spinal muscular
atrophy evidence review; (3)
presentations on newborn screening
topics such as the clinical and public
health impact of Critical Congenital
Heart Defects, quality measures in
newborn screening, and a review of
newborn screening technology; and (4)
updates from the Laboratory Standards
and Procedures workgroup, Follow-up
and Treatment workgroup, and
Education and Training workgroup. The
Committee will not be voting on a
proposed addition of a condition to the
RUSP. Agenda items are subject to
change. The final meeting agenda will
be available 2 days prior to the meeting
on the Committee’s Web site: https://
www.hrsa.gov/advisorycommittees/
mchbadvisory/heritabledisorders.
Members of the public will have the
opportunity to provide comments. All
comments are part of the official
Committee record. To submit written
comments or request time for an oral
comment at the meeting, please register
online by 12:00 p.m. on July 28, 2017,
at https://www.achdncmeetings.org/. To
ensure all individuals who have
registered and requested time for oral
comments are accommodated, the
allocated time for comments may be
limited. Individuals associated with
groups or who plan to provide
comments on similar topics may be
asked to combine their comments and
present them through a single
representative. No audiovisual
presentations are permitted. Written
comments should identify the
individual’s name, address, email,
telephone number, professional or
organization affiliation, background or
area of expertise (i.e., parent, family
member, researcher, clinician, public
health) and the topic/subject matter.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify Ann Ferrero using the address
and phone number above at least 10
days prior to the meeting.
Jason E. Bennett,
Director, Division of the Executive Secretariat.
[FR Doc. 2017–15113 Filed 7–18–17; 8:45 am]
BILLING CODE 4165–15–P
VerDate Sep<11>2014
18:49 Jul 18, 2017
Jkt 241001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS
Notice.
AGENCY:
ACTION:
Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
Alec Mirchandani, Florida Atlantic
University: Based on the report of the
inquiry conducted by Florida Atlantic
University (FAU), the Respondent’s
admission, and analysis conducted by
ORI, ORI found that Mr. Alec
Mirchandani, former post-baccalaureate
research volunteer in the Center for
Complex Systems and Brain Sciences,
Florida Atlantic University (FAU),
engaged in research misconduct in
research supported by National Institute
of Mental Health (NIMH), National
Institutes of Health (NIH), grant 1 R15
MH099590–01A1.
ORI found that Respondent engaged
in research misconduct by knowingly
and intentionally: (1) Fabricating the
results of the T-maze behavioral
experiment for control mice, (2)
falsifying the laboratory and vivarium
entry logs in an effort to cover up his
actions, and (3) reporting the fabricated
and falsified data to his laboratory
supervisors.
Specifically, ORI found that
Respondent knowingly and
intentionally:
• Fabricated the results that he
recorded for the T-maze behavioral
experiment in three of the five TMZ
control mice on the laboratory data
sheets and white board on fourteen (14)
of the sixteen (16) eligible days in June
2016, to make it appear as though he
had conducted the experiments;
• Falsified the animal transfer logs on
twelve (12) of the sixteen (16) eligible
days in June 2016, to make it appear as
though he had conducted the
experiments;
• Fabricated the times he recorded on
the laboratory data sheets on fourteen
(14) of the sixteen (16) eligible days in
June 2016, to make it appear as though
he had conducted the experiments;
• incorporated and recorded the
fabricated and falsified data with his
previous data in his laboratory notebook
and reported the results to his
laboratory supervisor and principal
investigator, such that the experimental
control data (five animals) for
experiments conducted from January
2016–June 30, 2016, were not accurately
represented.
SUMMARY:
PO 00000
Frm 00098
Fmt 4703
Sfmt 4703
33137
Mr. Mirchandani has entered into a
Voluntary Settlement Agreement with
ORI, in which he voluntarily agreed,
beginning on June 29, 2017:
(1) That if within two (2) years from
the effective date of the Agreement,
Respondent receives or applies for U.S.
Public Health Service (PHS) support,
Respondent agrees to have his research
supervised for a period of one (1) year,
beginning on the date of his
employment in a position in which he
receives or applies for PHS support, and
agrees to notify his employer(s)/
institution(s) of the terms of this
supervision. Respondent agrees that
prior to the submission of an
application for PHS support for a
research project on which the
Respondent’s participation is proposed
and prior to Respondent’s participation
in any capacity on PHS-supported
research, Respondent shall ensure that a
plan for supervision of Respondent’s
duties is submitted to ORI for approval.
The supervision plan must be designed
to ensure the scientific integrity of
Respondent’s research contribution.
Respondent agrees that he shall not
participate in any PHS-supported
research until such a supervision plan is
submitted to and approved by ORI.
Respondent agrees to maintain
responsibility for compliance with the
agreed upon supervision plan.
(2) To exclude himself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant for a period of one (1)
year, beginning with the effective date
of the Agreement.
FOR FURTHER INFORMATION CONTACT:
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8200.
Kathryn M. Partin,
Director, Office of Research Integrity.
[FR Doc. 2017–15159 Filed 7–18–17; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
E:\FR\FM\19JYN1.SGM
19JYN1
]]>Agencies
[Federal Register Volume 82, Number 137 (Wednesday, July 19, 2017)]
[Notices]
[Page 33137]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-15159]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has taken final action in the following case:
Alec Mirchandani, Florida Atlantic University: Based on the report
of the inquiry conducted by Florida Atlantic University (FAU), the
Respondent's admission, and analysis conducted by ORI, ORI found that
Mr. Alec Mirchandani, former post-baccalaureate research volunteer in
the Center for Complex Systems and Brain Sciences, Florida Atlantic
University (FAU), engaged in research misconduct in research supported
by National Institute of Mental Health (NIMH), National Institutes of
Health (NIH), grant 1 R15 MH099590-01A1.
ORI found that Respondent engaged in research misconduct by
knowingly and intentionally: (1) Fabricating the results of the T-maze
behavioral experiment for control mice, (2) falsifying the laboratory
and vivarium entry logs in an effort to cover up his actions, and (3)
reporting the fabricated and falsified data to his laboratory
supervisors.
Specifically, ORI found that Respondent knowingly and
intentionally:
Fabricated the results that he recorded for the T-maze
behavioral experiment in three of the five TMZ control mice on the
laboratory data sheets and white board on fourteen (14) of the sixteen
(16) eligible days in June 2016, to make it appear as though he had
conducted the experiments;
Falsified the animal transfer logs on twelve (12) of the
sixteen (16) eligible days in June 2016, to make it appear as though he
had conducted the experiments;
Fabricated the times he recorded on the laboratory data
sheets on fourteen (14) of the sixteen (16) eligible days in June 2016,
to make it appear as though he had conducted the experiments;
incorporated and recorded the fabricated and falsified
data with his previous data in his laboratory notebook and reported the
results to his laboratory supervisor and principal investigator, such
that the experimental control data (five animals) for experiments
conducted from January 2016-June 30, 2016, were not accurately
represented.
Mr. Mirchandani has entered into a Voluntary Settlement Agreement
with ORI, in which he voluntarily agreed, beginning on June 29, 2017:
(1) That if within two (2) years from the effective date of the
Agreement, Respondent receives or applies for U.S. Public Health
Service (PHS) support, Respondent agrees to have his research
supervised for a period of one (1) year, beginning on the date of his
employment in a position in which he receives or applies for PHS
support, and agrees to notify his employer(s)/institution(s) of the
terms of this supervision. Respondent agrees that prior to the
submission of an application for PHS support for a research project on
which the Respondent's participation is proposed and prior to
Respondent's participation in any capacity on PHS-supported research,
Respondent shall ensure that a plan for supervision of Respondent's
duties is submitted to ORI for approval. The supervision plan must be
designed to ensure the scientific integrity of Respondent's research
contribution. Respondent agrees that he shall not participate in any
PHS-supported research until such a supervision plan is submitted to
and approved by ORI. Respondent agrees to maintain responsibility for
compliance with the agreed upon supervision plan.
(2) To exclude himself voluntarily from serving in any advisory
capacity to PHS including, but not limited to, service on any PHS
advisory committee, board, and/or peer review committee, or as a
consultant for a period of one (1) year, beginning with the effective
date of the Agreement.
FOR FURTHER INFORMATION CONTACT: Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240)
453-8200.
Kathryn M. Partin,
Director, Office of Research Integrity.
[FR Doc. 2017-15159 Filed 7-18-17; 8:45 am]
BILLING CODE 4150-31-P
